1.
Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Pearlman Joel A, Sheth Veeral S, Khanani Arshad M, Indjeian Vahan B, Brunstein Flavia, Kuruvilla Denison et al.
Ophthalmol SciApr 20250 citationsClinical Trial
This Phase I study of anti-IL-33 drug RO7303359 for geographic atrophy found it safe but ineffective in modulating the IL-33 pathway, leading to development discontinuation.